<SEC-DOCUMENT>0001171843-24-005324.txt : 20240924
<SEC-HEADER>0001171843-24-005324.hdr.sgml : 20240924
<ACCEPTANCE-DATETIME>20240924060611
ACCESSION NUMBER:		0001171843-24-005324
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240924
DATE AS OF CHANGE:		20240924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XORTX Therapeutics Inc.
		CENTRAL INDEX KEY:			0001729214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267328
		FILM NUMBER:		241317460

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
		BUSINESS PHONE:		403-607-2621

	MAIL ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>f424b3_092324.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-267328</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Prospectus Supplement No. 11</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>(to Prospectus dated August 7, 2023)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: white"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>555,555 Common Shares Issuable Upon</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>XORTX THERAPEUTICS INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This Prospectus Supplement No. 11 (this &ldquo;<B>Prospectus Supplement</B>&rdquo;) amends and
supplements the Prospectus dated August 7, 2023 (the &ldquo;<B>Prospectus</B>&rdquo;) of XORTX Therapeutics Inc. (the &ldquo;<B>Company</B>&rdquo;),
which forms a part of our Registration Statement on Form F-1 (Registration No. 333-267328). This Prospectus Supplement is being filed
to amend and supplement the information included or incorporated by reference in the Prospectus with the information contained in this
Prospectus Supplement. The Prospectus and this Prospectus Supplement relate to the offer by us of 555,555 common shares issuable upon
exercise of 555,555 common share purchase warrants (the &ldquo;<B>Warrants</B>&rdquo;). The Warrants have an exercise price of $5.00 and
expire five years from the original date of issuance (October 7, 2027).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This Prospectus Supplement should be read in conjunction with the Prospectus, as it has been
further supplemented, which is to be delivered with this Prospectus Supplement. This Prospectus Supplement updates and supplements the
information in the Prospectus. If there is any inconsistency between the information in the Prospectus and this Prospectus Supplement,
you should rely on the information in this Prospectus Supplement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Our common shares are currently traded under the symbol &ldquo;XRTX&rdquo; on the TSX Venture
Exchange (the &ldquo;<B>TSXV</B>&rdquo;) and on the Nasdaq Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;). On September 20, 2024, the last
reported sale price of our common shares on the TSXV was CAD$2.47 per common share and on the Nasdaq was $1.75 per common share.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. You should review carefully the
risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; beginning on page 10 of the Prospectus and under similar
headings in any further amendments or supplements to the Prospectus before you decide whether to invest in our securities.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Neither the Securities and Exchange Commission, Canadian securities commission nor any domestic
or international securities body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">The date of this prospectus supplement is September 23, 2024.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>



<div align="center">

<div style="margin-top: 3pt; margin-bottom: 12pt;">

<div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div>

<p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington,
D.C. 20549</strong></p>

<p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p>

<p style="text-align: center;"><strong></strong></p>

<p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 <br />UNDER THE SECURITIES EXCHANGE
ACT OF 1934</strong></p>

<p style="text-align: left;"><strong></strong><strong>For the month of September 2024</strong></p>

<p style="text-align: left;"><strong>Commission File Number: 001-40858</strong></p>

<p style="text-align: center;"><font style="font-size: 12pt;"><strong>XORTX Therapeutics Inc.</strong></font></p>

<p style="text-align: center;"><strong>3710 &#8211; 33rd Street NW, Calgary, Alberta, T2L 2M1</strong></p></div>

<p>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.<br />Form 20-F
[&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p>

<p>&#160;</p><hr style="page-break-after: always;" noshade="noshade" />

<p><strong>SIGNATURE</strong></p>

<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</p>

<table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0">
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td style="text-align: left;" colspan="2" width="6%"><strong>XORTX Therapeutics Inc.&#160;&#160;&#160;&#160;</strong></td></tr>
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td colspan="2" width="6%">&#160;(Registrant)</td></tr>
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td width="6%">&#160;</td>
    <td style="text-align: left;" align="center" width="47%">&#160;</td></tr>
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td width="6%">&#160;</td>
    <td style="text-align: left;" align="center" width="47%"></td></tr>
  <tr valign="top">
    <td width="47%">Date: September 13, 2024</td>
    <td width="6%">&#160;</td>
    <td width="6%">By:&#160;</td>
    <td style="text-decoration: underline; text-align: left;" align="center" width="47%">&#160;&#160;&#160;&#160;<em>/s/ Allen Davidoff&#160;&#160;</em>&#160;&#160;</td></tr>
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td width="6%">Name:&#160;</td>
    <td style="text-align: left;" align="center" width="47%">Allen Davidoff</td></tr>
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td width="6%">Title:&#160;</td>
    <td style="text-align: left;" align="center" width="47%">Chief Executive Officer</td></tr>
  <tr valign="top">
    <td width="47%">&#160;</td>
    <td width="6%">&#160;</td>
    <td width="6%">&#160;</td>
    <td style="text-align: left;" align="center" width="47%"></td></tr>
  </table>

<p><!--On September 13, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br />(c) Exhibit 99.1. Press release dated September 13, 2024--><hr style="page-break-after: always;" noshade="noshade" />

<p style="text-align: center;"><u><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></u></p>

<table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><font style="font-size: 10pt;">99.1</font></td>
    <td width="20"><font style="font-size: 10pt;">&#160;</font></td>
    <td><font style="font-size: 10pt;">Report of Voting Results </font></td></tr>
  </table>&#160;</p>



<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="text-align: right; margin: 0pt 0"><B><A NAME="a_001"></A>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>XORTX THERAPEUTICS INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report of Voting Results</B><BR>
(Section 11.3 of National Instrument 51-102)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In accordance with section 11.3 of National Instrument 51-102 - <I>Continuous
Disclosure Obligations</I>, this report briefly describes the matters voted upon and the outcome of the votes at the Annual General and
Special Meeting of Shareholders of XORTX Therapeutics Inc. (the &ldquo;<B>Company</B>&rdquo;) held on September 12, 2024 at the offices
of the Company (the &ldquo;<B>Meeting</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in">1.</TD>
    <TD STYLE="text-align: justify"><B>Setting the Number of Directors at Seven</B></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">A resolution setting the number of directors of the board
to seven was approved. Proxies were received as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%">
    <P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">For the Motion:</P></TD>
    <TD STYLE="width: 80%">608,344 (68.430%)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left; background-color: White">
    <TD>Against:</TD>
    <TD>280,652 (31.570%)</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in">2.</TD>
    <TD STYLE="text-align: justify"><B>Election of Directors</B></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The shareholders voted by way of proxy and the following nominees were
elected as directors to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected
or appointed:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Director</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Votes For</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Votes Withheld</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Allen Davidoff</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">572,504</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">79.124%</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">151,052</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">20.876%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">William Farley</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">533,046</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73.670%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">190,510</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26.330%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Anthony J. Giovinazzo</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">487,453</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67.369%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">236,103</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32.631%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Abigail Jenkins</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">544,124</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75.201%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">179,432</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24.799%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Raymond Pratt</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">543,446</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75.108%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">180,110</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24.892%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Patrick Treanor</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">529,118</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73.127%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">194,438</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26.873%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Paul Van Damme</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">546,083</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75.472%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">177,473</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24.538%</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD STYLE="text-align: justify"><B>Appointment of Auditors</B></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">A resolution appointing Smythe LLP Chartered Professional
Accountants, as auditor of the Company until the next annual meeting of shareholders and authorizing the directors of the Company to fix
the auditor's remuneration was approved. Proxies were received as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%">For the Motion:</TD>
    <TD STYLE="width: 80%">739,390 (83.171%)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left; background-color: White">
    <TD>Withheld:</TD>
    <TD>149,606 (16.829%)</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in">4.</TD>
    <TD STYLE="text-align: justify"><B>Re-Approval of Stock Option Plan </B></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">A resolution re-approving and confirming the Company&rsquo;s
stock option plan as described in the management information circular dated August 9, 2024, including that the maximum number of common
shares reserved for issuance under the stock option plan at any given time is equal to ten percent (10%) of the issued and outstanding
common shares as at the date of grant of an option under the stock option plan, was approved. Proxies were received as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%">For the Motion:</TD>
    <TD STYLE="width: 80%">457,824 (63.274%)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left; background-color: White">
    <TD>Against:</TD>
    <TD>265,732 (36.726%)</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">For additional information, please see the Company&rsquo;s notice of meeting
and information circular dated August 9, 2024 filed on SEDAR in connection with the Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">DATED at Calgary, AB, September 13, 2024.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">
    <P STYLE="font-size: 10pt; margin: 0pt 0"><B>XORTX THERAPEUTICS INC.</B></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"><I>/s/ Charlotte May</I></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Charlotte May<BR>
Corporate Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !P 6D# 2(  A$! Q$!_\0
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MR/A-KVIE>;S4F^?UVJM?$W[5'B5O%W[0WC:\\TR)'?M:J&[+&<8_\=K]"O\
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M5$DGQ"\(J[$ V,N?^^EK[*$(K/9J"T:V^1\W4DO[-3ET/M3]E=0?@'X+/?\
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M;C-6:/J*<HSBI0=TQ]?D+^UQ_P GF7?_ &$++^:5^O'.WFOR'_:X/_&95V0
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MKNA_PDYLU/X*GZGCXR']IY:IQ^*GJ>G? OXGVGQ5^'.C:Y;-F1D$5PF<E)5
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M96T-K&D<,:QQJH"*O0#VJ?L<],5\MTT/K]4M3*\4?\B_JG_7I)_Z":\?_8J
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K,:4(WM'<S=%\.Z9X=LQ::990V-L&+B*! J[CU.!WJ_Y:^E/HJ#1)+1'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
